Logotype for DSM Firmenich AG

DSM Firmenich (DSFIR) Q3 2024 TU earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for DSM Firmenich AG

Q3 2024 TU earnings summary

8 Jul, 2026

Executive summary

  • Achieved strong organic growth and financial improvement in Q3 2024, with all business units contributing and synergy and transformation programs progressing well.

  • Animal Nutrition & Health (ANH) separation is well advanced, alongside strategic portfolio adjustments including the sale of marine lipids and yeast extracts.

  • Sustainability milestone reached with net-zero emissions targets validated by the Science Based Targets initiative, and a dedicated sustainability event planned for early 2025.

  • Upgraded full-year 2024 EBITDA outlook to approximately €2.1 billion, reflecting positive business momentum and a temporary profit boost from higher vitamin prices due to supply disruption.

Financial highlights

  • Q3 2024 sales rose 8% year-over-year to €3,244 million, with organic sales growth of 8% and group volume growth of 9%.

  • Adjusted EBITDA for Q3 2024 was €541 million, up 32% year-over-year, with margin improving to 16.7% (up 330bps).

  • Year-to-date Q3 2024 sales reached €9,542 million, up 4% year-over-year, and adjusted EBITDA was €1,517 million, up 13%.

  • Adjusted gross operating free cash flow for the first nine months was €879 million, reflecting disciplined working capital management.

  • Perfumery & Beauty delivered 11% volume growth and a 22.8% EBITDA margin; Taste, Texture & Health volumes up 13%, EBITDA up 21% to €162 million, margin 19.7%.

Outlook and guidance

  • Full-year 2024 adjusted EBITDA outlook raised to €2.1 billion, including a temporary profit boost of about €80 million in Q4 from higher vitamin prices.

  • CapEx expected at €0.8 billion for FY 2024, with D&A around €235 million per quarter and core income tax rate near 24%.

  • Expect continued strong business conditions into Q4, with regular seasonality in Perfumery & Beauty and Taste, Texture & Health, and a negative FX impact similar to Q3.

  • Anticipate Q1 2024 to benefit from vitamin price tailwinds, with €100 million expected in ANH and some improvement in Health, Nutrition & Care.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more